LOAd 703

Drug Profile

LOAd 703

Alternative Names: LOAd703

Latest Information Update: 15 Jun 2016

Price : $50

At a glance

  • Originator Lokon Pharma
  • Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Dendritic cell stimulants; Macrophage stimulants; Natural killer cell stimulants; T-cell receptor gene stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Pancreatic cancer

Most Recent Events

  • 15 Jun 2016 Phase-I/II clinical trials in Pancreatic cancer in USA (Intratumoural) before June 2016
  • 17 Mar 2016 Preclinical trials in Pancreatic cancer in Sweden (Intratumoural) before March 2016
  • 17 Mar 2016 Lokon Pharma plans a phase I/II trial for Pancreatic cancer in USA (Intratumoural) (NCT02705196)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top